Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.48
$0.210.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -20.25% | 24.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -20.25% | 24.84% | |||
| Cost of Revenue | -36.50% | 66.24% | |||
| Gross Profit | -18.64% | 21.83% | |||
| SG&A Expenses | -0.78% | 25.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.29% | 33.25% | |||
| Operating Income | 0.99% | -40.40% | |||
| Income Before Tax | -7.62% | -44.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.62% | -44.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.62% | -44.40% | |||
| EBIT | 0.99% | -40.40% | |||
| EBITDA | 1.11% | -40.78% | |||
| EPS Basic | -6.89% | -44.19% | |||
| Normalized Basic EPS | -6.88% | -44.20% | |||
| EPS Diluted | -6.89% | -44.19% | |||
| Normalized Diluted EPS | -6.88% | -44.20% | |||
| Average Basic Shares Outstanding | 0.69% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.69% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||